NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

特色學名藥的全球市場

Specialty Generics

出版商 Global Industry Analysts, Inc. 商品編碼 994860
出版日期 內容資訊 英文 181 Pages
商品交期: 最快1-2個工作天內
價格
特色學名藥的全球市場 Specialty Generics
出版日期: 2021年04月01日內容資訊: 英文 181 Pages
簡介

全球特色學名藥的市場規模,預計在分析期間(2020年∼2027年)將以18.4%的年複合成長率增長,從2020年的635億美元,到2027年達到2,074億美元。

本報告所分析的市場區隔之一的注射劑部門,在分析期間中預計將以19.6%的年複合成長率增長,達到1,499億美元。

本報告提供全球特色學名藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Akorn Inc.
  • Apotex Corp.
  • Endo International plc.
  • Mallinckrodt
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries
  • Valeant Pharmaceuticals

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:43公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP22833

Abstract:

Global Specialty Generics Market to Reach $207.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Specialty Generics estimated at US$63.5 Billion in the year 2020, is projected to reach a revised size of US$207.4 Billion by 2027, growing at aCAGR of 18.4% over the period 2020-2027. Injectables, one of the segments analyzed in the report, is projected to record 19.6% CAGR and reach US$149.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Types segment is readjusted to a revised 15.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 18% CAGR

The Specialty Generics market in the U.S. is estimated at US$18.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$36.4 Billion by the year 2027 trailing a CAGR of 18% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.5% and 15.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Select Competitors (Total 43 Featured) -

  • Akorn Inc.
  • Apotex Corp.
  • Endo International plc.
  • Mallinckrodt
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries
  • Valeant Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Inflammatory Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 25: USA Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 28: USA Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 31: Canada Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 34: Canada Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 37: Japan Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 40: Japan Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 43: China Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 46: China Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 49: Europe Current & Future Analysis for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 58: France Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 61: France Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 64: Germany Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 67: Germany Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 70: Italy Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 73: Italy Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 76: UK Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 79: UK Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Europe Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Europe 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 88: Asia-Pacific Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 91: Asia-Pacific Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Asia-Pacific Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Asia-Pacific 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 94: Rest of World Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
    • TABLE 97: Rest of World Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of World Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of World 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43